Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Article ID: 34875ece-48e7-46ac-9b84-3f81eaad766d

Updated: 9/4/2025

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/4/2025

Treatment of Resistant E. coli Infections

Combination Therapy for Metallo-β-lactamase-Producing Carbapenem-Resistant Enterobacterales

The Infectious Diseases Society of America recommends aztreonam combined with ceftazidime-avibactam for treating metallo-β-lactamase-producing carbapenem-resistant Enterobacterales, as aztreonam is not hydrolyzed by metallo-β-lactamases 1, 2, 3
This combination has shown significantly lower 30-day mortality (19.2% vs 44%) compared to other treatment options for these highly resistant infections 2, 3

REFERENCES

1

guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli. [LINK]

Journal of Microbiology, Immunology and Infection, 2023

2

diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the italian society of infection and tropical diseases (simit), the italian society of anti-infective therapy (sita), the italian group for antimicrobial stewardship (gisa), the italian association of clinical microbiologists (amcli) and the italian society of microbiology (sim). [LINK]

International Journal of Antimicrobial Agents, 2022

3

diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the italian society of infection and tropical diseases (simit), the italian society of anti-infective therapy (sita), the italian group for antimicrobial stewardship (gisa), the italian association of clinical microbiologists (amcli) and the italian society of microbiology (sim). [LINK]

International Journal of Antimicrobial Agents, 2022

← Return to Home